Johnson & Johnson's Inlexzo Device Approved for Bladder Cancer Treatment

Johnson & Johnson's Inlexzo device, a pretzel-shaped mechanical tube, has been approved to treat bladder cancer. The device delivers a tumor-killing drug over three weeks and has shown an 82% success rate in patients with high-risk bladder cancer that didn't respond to standard treatment. J&J forecasts peak annual sales of over $5 billion, three times higher than Wall Street estimates. Inlexzo's approval is expected to bring significant benefits to patients with this disfiguring and risky form of bladder cancer.

Johnson & Johnson (NYSE: JNJ) has received U.S. Food and Drug Administration (FDA) approval for its Inlexzo device, a novel intravesical drug releasing system designed to treat bladder cancer. Inlexzo, previously known as TAR-200, is indicated for adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors U.S. FDA approval of INLEXZO™ (gemcitabine intravesical ...^[1].

The device, which has a pretzel-shaped mechanical tube design, delivers gemcitabine, a tumor-killing drug, directly into the bladder over three weeks per treatment cycle. The extended local delivery of the medication is intended to improve treatment outcomes for patients who have not responded to standard BCG therapy or are not candidates for radical cystectomy U.S. FDA approval of INLEXZO™ (gemcitabine intravesical ...^[1].

Clinical trial results from the SunRISe-1 study, a single arm, open-label Phase 2b trial, demonstrated an 82% complete response rate among patients treated with Inlexzo. Additionally, 51% of these patients maintained a complete response for at least one year U.S. FDA approval of INLEXZO™ (gemcitabine intravesical ...^[1]. The device was well-tolerated, with the most common adverse reactions including urinary frequency, urinary tract infection, and dysuria U.S. FDA approval of INLEXZO™ (gemcitabine intravesical ...^[1].

The approval of Inlexzo is expected to bring significant benefits to patients with high-risk bladder cancer, offering a non-surgical alternative to those who have failed BCG therapy or are not suitable candidates for radical cystectomy. The device's innovative design and promising clinical results position it as a potential game-changer in the treatment of bladder cancer.

Johnson & Johnson has forecasted peak annual sales of over $5 billion for Inlexzo, which is three times higher than Wall Street estimates. The company's extensive portfolio in both pharmaceuticals and medical devices is expected to accelerate the innovation and commercialization of this new therapy U.S. FDA approval of INLEXZO™ (gemcitabine intravesical ...^[1].

References:
U.S. FDA approval of INLEXZO™ (gemcitabine intravesical ...^[1] https://www.prnewswire.com/news-releases/us-fda-approval-of-inlexzo-gemcitabine-intravesical-system-set-to-transform-how-certain-bladder-cancers-are-treated-302551487.html